The FDA has approved pirtobrutinib for certain adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.The new indication applies to adults who previously have ...

RWJBarnabas Health's commitment to enhancing access to care includes a transformative partnership with Rutgers University, including the Rutgers Cancer Institute -- the state's only NCI-designated ...

The former ‘Full House’ star announced his diagnosis during a November 2024 interview. Learn more about Dave’s condition.

Dave Coulier revealed that he has been recently diagnosed with tongue cancer - after previously beating 'very aggressive' non ...

Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...

The FDA’s Priority Review designation allows for a shortened review period (within 6 months) from the time of application acceptance.

Ahead of the upcoming American Society of Hematology annual meeting, a multicenter study published in the Journal of Clinical ...

The EC considered data from the TRANSCEND NHL 001 trial, in which 83 percent responded to the CAR T-cell therapy and 72 percent had a complete response.

Marks Breyanzi’s fourth indication in Europe, adding to existing approvals for several aggressive B-cell lymphomas.

Circulating tumor DNA (ctDNA) minimal residual disease (MRD) assessment at treatment completion provides superior prognostic accuracy compared with PET in large B-cell lymphoma. The CLARITY assay ...